Literature DB >> 24588649

Uses and misuses of treatments for ADHD. The second Birgit Olsson lecture.

Eric Taylor1.   

Abstract

BACKGROUND: Medication in attention deficit/hyperactivity disorder (ADHD) is so controversial that in some countries many children go untreated, while in others the prevalence of medication has become very high, and possibly even higher than the rate of ADHD. AIMS: This lecture addresses the reasons for overuse and the obstacles to adequate use.
METHODS: Clinical and scientific literature is reviewed, with emphasis on published meta-analyses and national guidelines. RESULTS AND
CONCLUSIONS: The lecture suggests that overuse is associated with economic forces affecting prescribers, while underuse may come about in some European countries because we have overestimated the hazards of drugs, overestimated the value of non-pharmaceutical interventions or underestimated the severity of disorder.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24588649     DOI: 10.3109/08039488.2013.804118

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  2 in total

1.  Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.

Authors:  Samuele Cortese; Nicoletta Adamo; Christina Mohr-Jensen; Adrian J Hayes; Sahar Bhatti; Sara Carucci; Cinzia Del Giovane; Lauren Z Atkinson; Tobias Banaschewski; Emily Simonoff; Alessandro Zuddas; Corrado Barbui; Marianna Purgato; Hans-Christoph Steinhausen; Farhad Shokraneh; Jun Xia; Andrea Cipriani; David Coghill
Journal:  BMJ Open       Date:  2017-01-10       Impact factor: 2.692

Review 2.  Attention-Deficit/Hyperactivity Disorder in Looked-After Children: a Systematic Review of the Literature.

Authors:  Renece Willis; Suyog Dhakras; Samuele Cortese
Journal:  Curr Dev Disord Rep       Date:  2017-07-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.